5381-78-2

Usage

InChI:InChI=1/C8H7N3O2/c1-10-5-9-7-4-6(11(12)13)2-3-8(7)10/h2-5H,1H3

Upstream product

• 553-90-2 Dimethyl oxalate 
• 94-52-0 5-nitrobenzimidazole 
• 1632-83-3 1-Methylbenzimidazole 
• 74-88-4 methyl iodide 
• 124-38-9 carbon dioxide 
• 99-56-9 4-Nitrophenylene-1,2-diamine 
• 94-52-0 6-nitro-1H-benzo[d]imidazole 
• 51-17-2 benzoimidazole 

Downstream Products

• 10394-38-4 1-methyl-1H-benzo[d]imidazol-5-amine 
• 82040-15-1 3-Methyl-6-nitro-1-[2-(4-nitro-phenyl)-2-oxo-ethyl]-3H-benzoimidazol-1-ium; bromide 
• 85721-83-1 1-methyl-2-benzoyl-5-nitrobenzimidazole 
• 85510-68-5 1-methyl-3-benzoyl-5-nitro-2-(1-methyl-5-nitro-2-benzimidazolyl)-2-benzimidazol-4-ine 
• 82040-12-8 1-methyl-5-nitro-3-phenacylbenzimidazolium bromide 
• 66108-85-8 1-methyl-5-nitro-1,3-dihydro-2H-benzo[d]imidazol-2-one 
• 15965-66-9 2-chloro-1-methyl-5-nitro-1H-benzoimidazole 
• 82040-21-9 N-methyl-4-nitro-2-(4-phenyl-1H-imidazol-1-yl)aniline 
• 82040-26-4 N-methyl-4-nitro-2-(4-(4-nitrophenyl)-1H-imidazol-1-yl)aniline 
• 1190604-03-5 3-methyl-8-phenyl-3H-imidazo[4',5':3,4]benzo[c]isoxazole 
• 1190604-04-6 8-(4-chlorophenyl)-3-methyl-3H-imidazo[4,',5':3,4]benzo[c]isoxazole 
• 1234801-38-7 (2-{[(3E)-5-amino-2,2-dimethylfuran-3(2H)-ylidene]amino}-4-nitrophenyl)methylformamide 
• 1234801-39-8 (2-{[(4E)-2-amino-1-oxaspiro[4.5]dec-2-en-4-ylidene]amino}-4-nitrophenyl)methylformamide 
• 26530-93-8 1-methyl-6-amino-1H-benzo[d]imidazole 

Relevant academic research and scientific papers

Endogenous X-C=O species enable catalyst-free formylation prerequisite for CO2reductive upgrading

CO2, the main component of greenhouse gas, is currently developed as a promising surrogate of carbon feedstock. Among various conversion routes, CO2undergoing catalytic reduction can furnish hydrogen/energy carriers and value-added chemicals, while specific metal-containing catalysts or organocatalysts are often prerequisite for smooth proceeding of the involved reaction processes. In this work, both formic acid and N-containing benzoheterocyclic compounds (including various benzimidazoles, benzothiazole, and benzoxazole) along with silanols could be synthesized with high yields (>90%) from catalyst-free reductive upgrading of CO2under mild conditions (50 °C). The endogenous X-CO species, derived from the N-methyl-substituted amide-based solvent [Me2N-C(O)-R], especially PolarClean, and O-formyl group [O-C(O)-H] of in situ formed silyl formate, were found to play a prominent promotional role in the activation of the used hydrosilane for reductive CO2insertion, as demonstrated by density functional theory (DFT) calculations and isotopic labeling experiments. Moreover, reaction mechanisms and condition-based sensitivity assessment were also delineated.

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Fusion of 2-(furan-2-yl)thiazole to 1-methyl-1H-benzimidazole

Methylation of 5(6)-nitro-1H-benzimidazole with methyl iodide in the presence of potassium hydroxide and N-methylpyrrolidin-2-one gave a mixture of isomeric 1-methyl-5-nitro- and 1-methyl-6-nitro-1H-benzimidazoles which were reduced with tin in concentrated aqueous HCl on heating. The resulting amines reacted with furan-2-carbonyl chloride in N-methylpyrrolidin-2-one to give furan-2-carboxamides which were treated with excess P2S5 in pyridine. Oxidation of isomeric furan-2-carbothioamides with K3[Fe(CN)6] in alkaline medium afforded a mixture of intramolecular cyclization products, 2-(furan-2-yl)-6-methyl-6H-imidazo[4,5-g][1,3]benzothiazole and 2-(furan-2-yl)-8-methyl-8H-imidazo[4,5-g][1,3]benzothiazole which were separated by column chromatography and identified.

Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template

In an effort to design inhibitors of human glutaminyl cyclase (QC), we have synthesized a library of N-aryl N-(5-methyl-1H-imidazol-1-yl)propyl thioureas and investigated the contribution of the aryl region of these compounds to their structure-activity relationships as cyclase inhibitors. Our design was guided by the proposed binding mode of the preferred substrate for the cyclase. In this series, compound 52 was identified as the most potent QC inhibitor with an IC50 value of 58 nM, which was two-fold more potent than the previously reported lead 2. Compound 52 is a most promising candidate for future evaluation to monitor its ability to reduce the formation of pGlu-Aβ and Aβ plaques in cells and transgenic animals.

ANTIFUNGAL AGENTS

Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: Rl, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.

Alkylation with Oxalic Esters. Scope and Mechanism.

Alkyl oxalates are well suited for use as standard synthetic reagents in N-, O-, or S-alkylations and often display an interesting regioselectivity.The mechanism seems to be a direct alkylation of the substrate anion.